Context: Glucagon-like peptide-1 agonists acutely lower serum glucagon. However, in the Liraglutide and b-Cell Repair (LIBRA) Trial, 48-week treatment with liraglutide yielded lower/ unchanged fasting glucagon but, surprisingly, enhanced postchallenge glucagonemia [measured by R&D Systems (Minneapolis, MN) assay].
G rowing recognition of the importance of a-cell dysfunction in type 2 diabetes (T2DM) has led to glucagon measurements becoming an increasingly common outcome of interest in clinical studies (1) . However, caution is warranted when measuring a hormone that circulates at low picomolar concentrations and has many related peptides with sequence homology. In this regard, both the sensitivity of an assay to detect the low circulating concentrations of glucagon and its specificity for glucagon (as opposed to glucagon-related peptides) can be critical to assay performance (1) (2) (3) . The impact of the assay potentially could be relevant to our recent unexpected findings on the effect of chronic liraglutide therapy on glucagon secretion in the Liraglutide and b-Cell Repair (LIBRA) Trial. Specifically, although glucagon-like peptide-1 (GLP-1) agonists are known to acutely lower serum glucagon, we found that 48-week treatment with liraglutide yielded lower/unchanged fasting glucagon but, surprisingly, enhanced postchallenge glucagonemia [measured by R&D Systems (Minneapolis, MN) assay] (4). Thus, to evaluate the potential impact of the assay on these findings, we have now measured glucagon from all 1222 samples in this trial using the highly-sensitive/specific Mercodia assay to compare the findings between the two assays.
Methods
The LIBRA Trial was a double-blind, randomized, placebocontrolled trial that was designed to determine whether liraglutide can preserve b-cell function over 48 weeks in early T2DM, following the initial amelioration of glucotoxicityinduced dysfunction using short-term intensive insulin therapy (IIT) prior to randomization (ClinicalTrials.Gov NCT01270789). The design, protocol, and main outcomes of the trial have been previously reported in detail (5) . In brief, patients with early T2DM underwent 4 weeks of IIT prior to randomization to either daily subcutaneous liraglutide or matching placebo injection for 48 weeks, with serial assessment by oral glucose tolerance test (OGTT) every 12 weeks. The study protocol was approved by the Mount Sinai Hospital Research Ethics Board, and all participants provided written informed consent.
Intervention
The study population and the protocol for the prerandomization IIT phase have been previously described in detail (5, 6) . Participants who achieved fasting venous glucose ,7.0 mmol/L 1 day post-IIT (a threshold indicative of the capacity of endogenous insulin secretion to maintain fasting glucose in the nondiabetic range) (5) were randomized 1:1 to either daily subcutaneous liraglutide 1.8 mg (titrated over 3 weeks) or identical placebo, as described previously (5) .
Laboratory measurements
Participants underwent 2-hour 75 g OGTT at randomization and every 12 weeks thereafter. Study medication was held on the morning of the OGTT, such that the last dose was administered ;24 hours earlier. As previously reported (4), initial glucagon measurements were performed by manual enzyme-linked immunosorbent assay from R&D Systems from samples at fasting and 30, 60, 90, and 120 minutes on each OGTT that were collected in chilled tubes with aprotinin and kept on ice before immediate storage at 280°C. This assay is reported to have no significant cross-reactivity with glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon-like peptide-2 and glicentin-related polypeptide, and ,12% cross-reactivity with oxyntomodulin. The assay has a detection limit of 14.7 pg/mL and analytical range 31.3 to 2000 pg/mL.
For the current analysis, all glucagon measurements were performed with glucagon enzyme-linked immunosorbent assay 10-1271-01 from Mercodia (Uppsala, Sweden) from frozen serum samples that were thawed on ice and maintained for ,1 hour at room temperature to maintain the stability of glucagon (7) . The assay has stated cross-reactivity with glicentin-related polypeptide (,0.0005%), GLP-1 (,0.3%), glucagon-like peptide-2 (,0.3%), and glicentin (0.8%), and 4.4% crossreactivity with oxyntomodulin. The assay has a detection limit of 1 pmol/L.
Outcomes
The previously reported main outcomes of the trial showed that the liraglutide group had better b-cell function and glycemic control than the placebo group at 48 weeks, but that these effects were not sustained after subsequent 2-week washout (5) . The current analysis focuses on the glucagon response, for which the area under the glucagon curve was determined on each OGTT by trapezoidal rule.
Statistical analysis
All analyses were conducted using SPSS 18.0 (Chicago, IL). The response profiles of glucagon (measured by both assays) to the OGTT at randomization, 12, 24, 36, and 48 weeks were plotted by treatment group (Fig. 1) . To assess agreement between the assays, we pooled the data for each of the five respective time points (0, 30, 60, 90, and 120 minutes) from all OGTTs. The total number of paired glucagon measurements by Mercodia and R&D Systems for each time point was as follows: 246 samples at fasting, 245 at 30 minutes, 245 at 60 minutes, 243 at 90 minutes, and 243 at 120 minutes. For each time point on the OGTT, we performed Spearman correlation analyses between each participant's mean glucagon at that time point from all five OGTTs as measured by Mercodia and their analogous mean glucagon measured by R&D Systems.
Results
Figure 1(a) shows the glucagon response profiles measured by R&D Systems assay from the OGTT at each of randomization, 12 weeks, 24 weeks, 36 weeks, and 48 weeks in the liraglutide arm (n = 26) and placebo arm (n = 25). These glucagon profiles, which were previously presented in their original units of pg/mL (4), have been reproduced in this study in pmol/L to facilitate comparison of the R&D Systems and Mercordia results. With glucagon measured by R&D Systems assay, liraglutide induced the following response profile compared with placebo: (1) lower/similar fasting glucagon, (2) an enhanced postchallenge glucagonemic excursion, and (3) a delayed time to peak glucagon [ Fig. 1(a) ]. Figure 1(b) shows the glucagon response profiles when measured by Mercodia assay. Fasting glucagon by Mercodia assay was higher in the liraglutide arm than placebo at 12 weeks (8.5 6 3.4 vs 6.4 6 2.3 pmol/L, P = 0.01), with no significant differences between the groups at other visits (all P $ 0.30). Importantly, unlike with the R&D Systems assay, there was no difference in area under the glucagon curve between the liraglutide and placebo arms at any visits (all P $ 0.44) (data not shown).
The R&D Systems and Mercodia assays also showed differences in the overall glucagon secretory profiles in response to the OGTT (Fig. 1) . First, whereas the R&D Systems assay yielded a pronounced postchallenge rise in glucagon, the Mercodia assay indicated a much more modest incremental increase following the oral glucose challenge. At 120 minutes postchallenge, the R&D Systems assay indicated that serum glucagon was back to its fasting level, whereas the Mercodia assay showed that circulating glucagon was now much lower than at fasting. Finally, as shown by the scales of the respective y-axes in Fig. 1 , the R&D Systems assay indicated 
Discussion
Our previously reported findings by R&D Systems assay consistently demonstrated an enhanced postchallenge glucagon response in the liraglutide arm across the duration of the trial, but was unanticipated (4) . As such, we have now measured glucagon from all of the trial samples using the assay from Mercodia, which has not replicated the R&D Systems findings. In particular, the Mercodia assay did not indicate an enhanced postchallenge glucagonemic response in the liraglutide arm as compared with placebo.
In this context, our paired measurements of glucagon by two assays in .1200 samples have provided a unique analytic opportunity for insight relevant to the clinical measurement of this hormone. Notably, the glucagon measurement by R&D Systems was consistently ;20 pmol/L higher than that of Mercodia, suggestive of a systematic difference between the assays in sensitivity or cross-reactivity. It seems likely that cross-reactivity with another analyte (such as the glucagon-related peptides oxyntomodulin and glicentin) may be contributing to the differences in the glucagon concentrations measured by the two assays. The R&D Systems assay reports ,12% crossreactivity with oxyntomodulin, whereas the Mercodia assay reports 4.4% cross-reactivity with this peptide. We have also observed differences between the assays in their cross-reactivity with glicentin (unpublished observation). Of note, although it is anticipated that a nutrient challenge should stimulate the secretion of oxyntomodulin and glicentin, the correlation between the R&D Systems and Mercodia assays in their glucagon measurements was much better at the postchallenge time points than at fasting. It remains unclear whether differences in the relative proportions (as opposed to concentrations) of the peptides in question (glucagon, oxyntomodulin, glicentin) between the fasting and postchallenge states are responsible in this regard, or if cross-reactivity with other factors may also be present. Although the basis for the differences between the two assays remains uncertain, these data clearly demonstrate the potential impact of assay selection when measuring glucagon in clinical studies.
A strength of this study is the double-blind, placebocontrolled assessment of the five-point response profiles of glucagon measured by two different assays on five serial OGTTs across 48 weeks in subjects randomly assigned to daily liraglutide or placebo injection. Conversely, the observed differences between the R&D Systems and Mercodia assays preclude definitive conclusion. Rather, our data emphasize the critical importance of considering potential assay differences when interpreting glucagon measurements from clinical studies. Another factor to consider is that, with liraglutide last administered ;24 hours before each OGTT, it remains unclear whether any observed effects on the glucagon response are due to the medication or its withdrawal after chronic exposure. Indeed, the latter interpretation potentially may be supported by the absence of differences in fasting GLP-1 between the liraglutide and placebo arms in the LIBRA Trial (because suppression of basal GLP-1 might be anticipated in the ongoing presence of liraglutide) (8) .
In summary, the Mercodia and R&D Systems assays did not yield the same findings for the effect of chronic liraglutide therapy on glucagon secretion in the LIBRA Trial. Although the R&D Systems assay indicated enhanced postchallenge glucagonemia with liraglutide, this was not seen with the Mercodia measurements. Although neither assay demonstrated lower postchallenge glucagonemia with liraglutide vs placebo, their differences preclude definitive conclusion. These data highlight the caveat that the measurement of glucagon in biologic samples remains challenging, such that caution is warranted in its evaluation in clinical studies.
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